Biogen Reports PLEGRIDY Two-Year Data Confirms Maintenance of Efficacy, Safety in MS Patients
September 11, 2014 at 07:32 AM EDT
Today Biogen Idec (NASDAQ: BIIB) announced new data from the second year of its Phase 3 ADVANCE clinical trial that show the positive ...